Production-scale preparation of parenteral veterinary emulsions begins with the oil phase because sorbitan monooleate-containing oily vehicles cannot be aseptically filtered through 0.22 µm sterilising-grade membranes at room temperature. The oil phase is heated to 60–70 °C and passed through a 10 µm clarification filter into a depyrogenated stainless-steel vessel, where sorbitan monooleate is dissolved at 0.5–2.0% w/w. Ph. Eur. 5.1.1 permits dry-heat sterilisation of oily vehicles at 160 °C for 2 h; for sorbitan ester systems this is performed under nitrogen overlay because thermal exposure above 160 °C accelerates peroxide formation and colour changes. The peroxide value of a freshly sterilised oil phase must remain below 5 meq O₂/kg when retinol acetate or vitamin E acetate is incorporated, as oxidation products from sorbitan monooleate initiate free-radical losses of these co-solubilised vitamins during storage at 25 °C. The aqueous phase is then added through a rotor-stator homogeniser operating at 12–18 m/s tip speed; the coarse emulsion is recirculated through a high-pressure valve homogeniser at 500–800 bar until laser diffraction by ISO 13320:2020 confirms D50 1–5 µm. The finished W/O emulsion is not terminally filtered because the dynamic viscosity at 25 °C exceeds 450 mPa·s; it is filled aseptically under Grade A air supply per EU GMP Annex 1. Quality release includes sterility testing according to USP <71> or Ph. Eur. 2.6.1, bacterial endotoxin testing according to USP <85> or Ph. Eur. 2.6.14, and subvisible particle evaluation according to USP <788> for opaque emulsions. Published data for this exact veterinary W/O vehicle configuration is limited, so each batch must be qualified for droplet size distribution and viscosity after terminal sterilisation.

The main operational boundary for parenteral use is hydrolytic degradation. In unbuffered W/O emulsions with an internal aqueous phase at pH 2.0, the sorbitan ester loses emulsifying capacity within 3–6 months at 25 °C because free fatty acids are released and partition into the oil phase. Batch-to-batch viscosity differences are therefore expected when the ester acid value rises above 2 mg KOH/g; incoming ester lots are tested for acid value, hydroxyl value, and peroxide value before use. The oil phase should be blanketed with nitrogen after opening to avoid moisture uptake; at storage above 60% relative humidity, the ester absorbs water and can form a hazy oil phase that interferes with droplet size reproducibility.

Why Does Endpoint Torque Fluctuate in Sorbitan Ester-Wetted Tablet Granules?

In high-shear wet granulation of veterinary tablet blends, sorbitan monostearate is not dry-blended with the lactose-cellulose matrix because its melt point range of 54–57 °C overlaps with the frictional heating generated at impeller speeds above 4 m/s. Instead, the ester is dispersed into the binder phase at 60–65 °C, either as a melt with polyethylene glycol 6000 or as a suspension in a 5% w/w PVP K30 aqueous solution. The molten ester lowers the surface tension of the granulating fluid and allows wetting of active substances with contact angles above 90°, measured by sessile drop goniometry according to ASTM D7490-13. When the binder is sprayed at 60 °C into a premix agitated at 5–7 m/s impeller tip speed, the granulation torque increases only after liquid saturation reaches 80–90% of the capillary state. Production-scale mixer logs record endpoint torque fluctuations of ±15% when the ester concentration in the binder exceeds 1.0% w/w because the lipophilic layer retards water penetration into microcrystalline cellulose. The endpoint is therefore confirmed by a two-stage impeller power draw plateau lasting 45–90 seconds rather than by a fixed massing time. Drying in a fluidised-bed dryer with inlet air at 60 °C reduces granule moisture to 1.5–2.5%; residual moisture below 1.2% causes granule attrition, while moisture above 3.0% causes punch filming during compression. Tablets compressed from these granules are tested for disintegration according to USP <701> or Ph. Eur. 2.9.1; tablets containing more than 2.0% sorbitan monostearate can exceed 15 minutes disintegration in 0.1 M HCl at 37 °C because the ester creates a hydrophobic pore network. Compression tooling must be maintained below 40 °C because the ester softens and deposits on the punch faces.

Where aqueous solubility of a veterinary active substance remains below 1 mg/mL across pH 2.0–8.0, a true solution is not feasible without co-solvent, cyclodextrin, or micellar solubilisation. Sorbitan esters alone do not form micelles at practical aqueous concentrations because their HLB values are below 10; they function as wetting and co-emulsifying agents when blended with polysorbate 80 to raise the effective HLB to 12–14. The working concentration of sorbitan monolaurate in oral solutions and reconstitutable suspensions is maintained at 0.05–0.5% w/v, and it must be dispersed under high-shear before the aqueous phase is added to avoid translucent gel-like aggregates. In aqueous stock solutions stored at 2–8 °C, sorbitan monolaurate can lose wetting efficiency through hydrolysis of the ester bond; the release of lauric acid reduces pH by 0.3–0.8 units over 12 months in unbuffered systems. Compounding records therefore include a phosphate-citrate buffer at 10–25 mM and preservative efficacy testing according to USP <51> or Ph. Eur. 5.1.3. For reconstitutable powders, the dried dispersion is milled through a 0.5 mm screen, and the bulk powder is evaluated at 60% RH; sorbitan ester-coated particles show a water vapour sorption mass gain below 2.0% after 24 h, which is a relevant stability marker for moisture-sensitive actives such as amoxicillin trihydrate. The coating step must not exceed 45 °C because higher temperature softens the ester layer and agglomerates the powder.

Dry Powder Coating, Solvent Retained Moisture, and Blend Uniformity Limits

For oral powders containing poorly wettable active substances with median particle diameters below 50 µm, sorbitan tristearate is applied as a 10–20% w/w solution in isopropanol from a solvent-based fluidised bed coater with inlet air at 40–50 °C. The coating solution is sprayed through a 1.0 mm two-fluid nozzle at atomising air pressure of 2.0–3.0 bar; the resulting ester coating deposits at 0.5–2.0% w/w on the particle surfaces and reduces interparticle cohesion in subsequent sachet filling. Residual isopropanol is controlled below 5000 ppm because the solvent is Class 3 under ICH Q3C(R8), and batch release for solvent-treated veterinary powders requires headspace gas chromatography according to USP <467>. Blend uniformity is assessed after the coating step using stratified sampling and acceptance criteria from USP <905> or Ph. Eur. 2.9.40; production-scale ribbon blender experience shows that overcoating above 2.0% w/w can shift the particle size distribution to a bimodal profile and raise relative standard deviation above 5.0% for low-dose actives. Powder flow through the dosing auger is measured by Carr index and angle of repose; ester-coated powders with residual moisture above 3.0% at 60% RH show bridging in hoppers because the sorbitan tristearate layer plasticises and forms liquid bridges between particles. The process boundary for ambient humidity is therefore set at 50% RH unless the filling line is fitted with dry-air purging.

When Feed Premix Pelleting Exceeds the Sorbitan Ester Melt Point

Sorbitan monostearate in feed premix granules is used as a hydrophobic binder for fat-soluble vitamins A, D₃, and E because its melt point of 54–57 °C is below the conditioning temperature of 70–85 °C used in pelleting. This temperature gap creates a process conflict: the ester melts during steam conditioning and can migrate to the pellet surface, where it increases die friction and reduces pellet durability after cooling. When the premix contains 1.0–3.0% w/w sorbitan monostearate, the pellet mill motor load rises by 10–20% compared with ash-based pellet binders, and the Holmen durability index falls below 85% when the conditioner residence time exceeds 30 seconds. To limit the migration, the ester is pre-mixed with calcium carbonate or sepiolite at 1:2 to 1:4 ratios before steam addition; this solid carrier absorbs the molten ester and maintains free-flowing granule structure. The use of the resulting premix in complete feed falls under the hygiene requirements of Regulation (EC) No 183/2005, and the ester component must be checked for peroxide value below 5 meq O₂/kg because oxidised sorbitan esters accelerate vitamin A acetate losses by more than 15% after 8 weeks at 40 °C. Batch records for spray-cooled premixes recommend discharge air temperature below 30 °C; higher discharge temperatures cause partially solidified sorbitan monostearate to bind the carrier particles into brittle agglomerates that generate dust during pneumatic conveying. The operational limit for water activity is 0.60 because free water competes with the ester for the carrier surface and causes phase separation in the pellet conditioner. Published data for this specific sorbitan ester–sepiolite premix combination is limited; the above operating limits are derived from standard pelleting trials and must be re-verified on each line.

Typically, liquid-filled hard capsule manufacturing lines for veterinary products require a fill matrix viscosity below 800 mPa·s at 40 °C during dosing, since production capsule fillers are thermostated at 35–45 °C. Sorbitan monooleate is blended at 5–20% w/w with medium-chain triglycerides or glycerol monooleate to suspend micronised active substances with particle sizes below 20 µm. The ester reduces sedimentation velocity in the liquid fill by increasing the low-shear viscosity, but it does not produce a structured thixotropic gel unless combined with fumed silica at 0.5–1.5% w/w. Capsule shell compatibility is assessed at 23 °C and 45% RH because hard gelatin shells become brittle below 40% RH and soften above 55% RH. Oxidised sorbitan monooleate introduces aldehydes that can cross-link gelatin and delay disintegration; therefore the ester used in capsule fills is controlled for peroxide value below 2 meq O₂/kg and for acid value below 2 mg KOH/g. Dissolution testing of the filled capsules is performed according to USP <711> or Ph. Eur. 2.9.3; release failures in early-stage formulation work are commonly traced to insufficient dispersion of the hydrophobic fill matrix in the dissolution medium unless a paddle speed of 75 rpm and sink conditions are maintained. The operational boundary for the fill process is 45 °C; above this temperature the viscosity drops rapidly, but the sorbitan monooleate may begin to partition away from the suspended active substance and create a lipid layer at the fill nozzle, leading to weight variation outside ±5% on capsule fillers operating at 30,000 capsules/hour.